Hematology Markets for Recombinant Therapies

Transcription

1 Hematology Markets for Recombinant Therapies Products, Supply Chains, Markets, Players & Forecasts Report Brochure Greystone Research associates

2 H e m a t o l o g y M a r k e t s f o r R e c o m b i n a n t T h e r a p i e s Greystone Research Associates is pleased to announce the publication of a new market study. Hematology Markets for Recombinant Therapies: Products, Supply Chains, Markets, Players and Forecasts is a comprehensive evaluation and analysis of the products, markets and suppliers in this important therapeutic market sector. The study is designed to provide pharmaceutical and biotech decision makers, product developers, healthcare marketers, and supply chain participants with a detailed understanding of the relationships, product characteristics and commercial opportunities for recombinant therapies indicated for hematology conditions. Provider organization business managers, healthcare administrators and investors will also benefit from this study. Engineered Therapies for Treating Blood-related Conditions Hematology conditions and diseases include some of the most intractable ailments to treat. The advent and growing availability of recombinant blood factors and related therapy-class drugs has created new clinical standards and protocols for treating a number of blood-associated conditions. This list includes hematopoietics for treating anemia, colony stimulating factors for treating neutropenia, and a fusion protein for treating hemophilia, as well as monoclonal antibodies and an a cytokine that acts as a thrombopoietic growth factor. The total global market for recombinant drugs indicated for hematology was $23 billion in There are fourteen active late-stage (phase 3 or 4) clinical trials for development-stage therapies. This report examines each recombinant therapy in detail and forecasts the market for each indication. Report Value Matrix Managed Care Management Consultants Financial Analysts Product Developers Component Suppliers CMOs, CSOs Pharma Product Device Suppliers Biotech Marketers & Strategists Clinical Device Distributors Pharma Regulators Recombinant Drug Ecosystem

3 Table of Contents Executive Summary Hematology Therapeutics - The Market Opportunity Treating Blood-related Conditions Therapeutic Demand Drivers Demographic Factors Competitive Landscape Risk Factors Sourcing & Supply Chain API Final Product Labeler Supplier Ecosystem Collaborations & Relationships Hematology Indications & Markets Antihemophilic Factors Antithrombins Coagulation Factors Colony Stimulating Factors Erythropoiesis Stimulating Proteins Platelet Inhibitor Thrombopoietic Growth Factor TPO Mimetic Recombinant Therapies in Hematology Product Analysis Antithrombins Blood Factors Colony Stimulating Factors Cytokines Fusion Proteins Hematopoietics Monoclonal Antibody Market Data & Forecasts Market Factors Regulatory Issues Packaging and Administration Biosimilars Managed Care Initiatives Company Profiles

4 Comprehensive Assessments & Forecasts What You Will Learn What are the recombinant drugs indicated for hematology conditions that have been given marketing authorization by the FDA or the EMA? Who supplies the API; the finished product? Who is the labeler; the marketer? What is the host system? What are the hematology drug classes targeted by recombinant therapies; what are their growth rates? Who are the major biotech companies operating in the hematology space; what are their facilities, and where are they located? What are the as-supplied characteristics for recombinant hematology therapies and how are they administered? What is the probable impact of biosimilars on the hematology sector in North America; in Europe? What does the market look like today? What is the forecast for how it will look in 2022? What will be the impact of economic, technology, and regulatory factors on the commercial potential of recombinant therapies approved for treating hematology conditions? Report Format and Availability This report is available electronic format. A site license for a single physical location and a corporate license are also available. Custom licensing options to address specific company user requirements are available by calling client services at , or by ing clientservices@greystoneassociates.org. Methodology Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations. Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations. Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques. About Greystone Research Associates Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

5 How To Order Ordering Information Orders may be placed via postal mail, or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. Payment We accept the following forms of payment: Company Check: Please make checks payable to Greystone Associates Credit Cards: We accept MasterCard, Visa and American Express Wire Transfers: See Wire Transfers below for more information Fax to: or to clientservices@greystoneassociates.org Orders Outside the U.S. Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a $50 per copy shipping and handling charge for international shipments. Wire Transfers: TD Banknorth 300 Franklin Street Manchester, NH (Call for Account Information) Mailing Address: Greystone Research Associates Client Services P.O. Box 1362 Amherst, NH Hematology Markets for Recombinant Therapies Products, Supply Chains, Markets, Players and Forecasts Select Format Price (U.S. funds) Total Single User $2, Site License $4, Corporate License $6, Total Payment (U.S. funds) Method of Payment: Company Check Wire Transfer (International) Card Number: Name on Card Expiration Date: Card CVV Signature Billing Information Name: Title: Company: Street Address: City,State/Province: Country/Postal Code: Phone: Fax: Shipping Information Click here if same as Billing Information Name: Title: Company: Street Address: City,State/Province: Country/Postal Code: Phone: Fax: